Atlas FDA

JUVEDERM ULTRA XC AND JUVEDERM ULTRA PLUS XC

FDA premarket approval P050047/S030 · decided 2013-03-11

Approval details

PMA number
P050047
Supplement
S030
Supplement type
Real-Time Process
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
JUVEDERM ULTRA XC AND JUVEDERM ULTRA PLUS XC
Generic name
Implant, dermal, for aesthetic use
Applicant
Allergan
Date received
2012-12-26
Decision date
2013-03-11
Days to decision
75 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Irvine, CA
Statement
APPROVAL FOR AN EXTENSION OF THE SHELF-LIFE FROM 18 MONTHS TO 20MONTHS FOR THE 1ML SYRINGE; AN INCREASE IN THE ONOETHYLGLYCINEXYLIDIDE (MEGX) IMPURITY SPECIFICATION FROM 2.5% TO 3.5% W/W OF THE LABEL STRENGTH AND TOTAL IMPURITIES FROM 3.0% TO 4.3% OF LABEL STRENGTH.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
NATRELLE INSPIRA Single Use Sizers for Gel Implants (K203229)Allergan2021-06-02
TrueTear Intranasal Tear Neurostimulator (K193589)Allergan2020-08-31
Natrelle 133 Plus MICROCELL Tissue Expander (K180826)Allergan2018-12-21
Natrelle 133S Tissue Expander (K182054)Allergan2018-08-29
TrueTear Intranasal Tear Neurostimulator (DEN170086)Allergan2018-05-17
SERI SURGICAL SCAFFOLD (K123128)Allergan2013-04-25